5
Clinical Trials associated with β-globin restored autologous hematopoietic stem cells (Hemogen Gene)A Pilot Clinical Study Evaluating the Safety and Efficacy of HGI-001 Injection in Patients with Transfusion-Dependent Beta-Thalassemia
Start Date01 Dec 2024 |
Sponsor / Collaborator- |
An Open, Multi-center, Phase I Clinical Study on the Safety and Efficacy of HGI-001 Injection in Patients with Transfusion-Dependent Β-Thalassemia.
This is a single-arm, open label, multi-center, single-dose Phase 1 clinical trial in subjects with transfusion dependent β-thalassaemia. The study aims to evaluate the safety and efficacy of autologous lentiviral-transduced CD34+ human hematopoietic stem cells (hHSCs) using the gene therapy product HGI-001.
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia(Child)
This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients
100 Clinical Results associated with β-globin restored autologous hematopoietic stem cells (Hemogen Gene)
100 Translational Medicine associated with β-globin restored autologous hematopoietic stem cells (Hemogen Gene)
100 Patents (Medical) associated with β-globin restored autologous hematopoietic stem cells (Hemogen Gene)
100 Deals associated with β-globin restored autologous hematopoietic stem cells (Hemogen Gene)